2018 ACR/ARHP Annual Meeting

October 19-24, 2018. Chicago, IL.

View by Number View by Title View Sessions

View by Date

Abstract Number: 840

The CCL21/CCR7 Axis Drives Vascular, Inflammatory and Destructive Remodeling in Rheumatoid Arthritis
Abstract Number: 841

TNFR2 Inactivation Reduces Psoriatic Inflammation in Mice Via Down-Regulating Dendritic Cell Expansion and Inhibiting IL-23/IL-17 Pathways
Abstract Number: 842

Interleukin 17 Receptor D (IL-17RD) Is Regulated By Pro-Inflammatory Cytokines and Plays a Role in the Development of Collagen-Induced Arthritis
Abstract Number: 843

Localization of the Voltage-Gated Sodium Channel 1.7 in Peripheral Monocytes Contributes to Activation of BAFF Signaling in Monocytes of Patients with Primary Sjögren’s Syndrome
Abstract Number: 844

Differential Roles of Tnfα-TNFR1 and Tnfα-TNFR2 in the Differentiation and Function of Induced CD4+Foxp3+ Treg Cells in Autoimmune Diseases
Abstract Number: 845

New Insights in Lupus Dermatitis: Differential Regulation and Roles of Tissue-Resident Dendritic Cell Subsets in the Pathogenesis of Autoimmune Skin Inflammation
Abstract Number: 846

CD14 Deficiency Dampens Osteoclastogenesis and Alters Bone Remodeling in a Murine Model of Osteoarthritis
Abstract Number: 847

Basic Calcium Phosphate Crystals Induce Osteoarthritis-Associated Changes in Chondrocyte Phenotype through Activation of Calcium/Calmodulin Kinase 2
Abstract Number: 848

A2A Adenosine Receptor Stimulation Switches TGF-β Signaling to Promote Chondrocyte Proliferation and Cartilage Regeneration
Abstract Number: 849

Constructing a Macrophage Infiltration Timeline in a Murine Model of Osteoarthritis
Abstract Number: 850

Long Term Efficacy of Cartilage Repair Induced By scSOX9 in Situ with Bone Marrow-Derived Mesenchymal Stem Cells
Abstract Number: 851

Integrin Mac-1 Potentiates Neutrophil Adhesion and NET Release in Antiphospholipid Syndrome
Abstract Number: 852

Antigenic Property of Prothrombin/HLA-DR Complex on Procoagulant Cells in Patients with Antiphospholipid Syndrome
Abstract Number: 853

Enhanced Type I Interferon Gene Signature in Primary Antiphospholipid Syndrome: Association with Earlier Disease Onset and Preeclampsia
Abstract Number: 854

First and Recurrent Thrombosis Risk after 1897 Patient-Years of Follow-up: Prospective Results from Antiphospholipid Syndrome Alliance for Clinical Trials and International Networking (APS ACTION) Clinical Database and Repository (“Registry”)

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].